UK-based pioneering Life Science Technology
Metis Partners presents an opportunity to acquire an instrument with a microfluidic consumable stream plus intellectual property (“IP”) in the rapidly expanding protein-protein interaction and characterisation market. We are selling the business and IP assets owned by Fluidic Analytics Limited (in Administration) (“Fluidic Analytics” or the “Company”), a UK-based pioneering lab tools and instrumentations company backed by circa £50m in investment to date from PE, VC and other funds. The Company is dedicated to transforming the world's understanding of protein interactions and their behaviour.
Established in 2013 as a spin-out from the University of Cambridge, UK, the Company was formed to commercialise over a decade’s worth of research into the behaviour of disordered proteins. The Company designs, develops and manufactures tools, software and services for protein characterisation, aiming to make understanding of protein interactions widespread across research and industry. The Company’s products and services, including a proprietary system which enables quantification and characterisation of protein interactions, empower customers in neuroscience (Alzheimer’s), cancer research and immunology to gain valuable insights in areas such as disease mechanisms, drug targets, diagnosis, and screening for biological drugs.
- With over 60 customers across more than 20 countries, 30 peer-reviewed publications and investment of circa £50m to date, it represents a strategic opportunity to enter the protein-protein interaction and characterisation market which is expected to grow at a CAGR of 13.7% from 2021 to 2026, reaching a size of $23.9b;
- Acquire an extensive patent portfolio, complemented by exclusive worldwide licenses, focused on innovative microfluidic diffusion sizing technology that allows kinetic measurements (Kd) of protein interaction as well as quantitation of biological molecules (e.g. antibodies) and their targets. These assets underpin the Company's products and services and offer significant potential for future revenue generation;
- Acquire additional IP assets including proprietary software, key organisational knowledge and a robust trade mark portfolio; and
- Other assets for sale include high-quality lab equipment which empower the Company's offerings and would ensure a smooth transition for a potential acquirer, enhancing its competitive advantage.
Please be advised that a deadline for offers has been set for 5pm (GMT) and 12pm (EST) on Tuesday 28th November 2023.